Literature DB >> 7053846

Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide.

A J Schroit, I J Fidler.   

Abstract

Various vesicle structures and lipid compositions have been studied to identify the optimal type of liposome for delivery of the macrophage-activating agent muramyl dipeptide (MDP) to macrophages. Evaluation of the ability of liposomes to be phagocytosed by macrophages established that optimal initial rates of engulfment were obtained when multilamellar vesicles (MLV) composed of distearoylphosphatidylcholine (18:0 PC): phosphatidylserine (PS) (7:3 mol ratio) were used. MLV composed exclusively of 18:0 PC were phagocytosed at rates greater than or equal to those of MLV composed of egg phosphatidylcholine (PC):PS, whereas MLV composed only of egg PC were very poorly phagocytosed. Although phagocytosis was enhanced by incorporation of PS into MLV, the inclusion of PS brought about significant enhancement in liposome permeability in the presence of serum. The inclusion of PS, however, was a requirement for the delivery of MLV to the lungs following i.v. injection into mice whether used in conjunction with 18:0 PC or egg PC. Activation of macrophages to become tumoricidal against syngeneic tumor cells wtih liposome-encapsulated MDP was superior in both degree and duration when MLV composed of 18:0 PC:PS (7:3 mol ratio) were used. MLV were found to be superior to large unilamellar vesicles containing equal amounts of lipid and entrapped MDP. On the other hand, higher levels of macrophage activation were obtained when an equivalent amount of a lipophilic MDP derivative, muramyltripeptide:phosphatidylethanolamine, was incorporated into the liposome bilayer irrespective of whether the adjuvant was incorporated in liposomes composed of 18:0 PC:PS or egg PC:PS.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7053846

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

Review 1.  Platelet-derived microparticles and the potential of glycoprotein IIb/IIIa antagonists in treating acute coronary syndrome.

Authors:  Ximing Li; Hongliang Cong
Journal:  Tex Heart Inst J       Date:  2009

2.  Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells.

Authors:  Joy Wolfram; Krishna Suri; Yi Huang; Roberto Molinaro; Carlotta Borsoi; Bronwyn Scott; Kathryn Boom; Donatella Paolino; Massimo Fresta; Jianghua Wang; Mauro Ferrari; Christian Celia; Haifa Shen
Journal:  J Microencapsul       Date:  2014-03-24       Impact factor: 3.142

3.  Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: quantitative assessment of outer-leaflet lipid by prothrombinase complex formation.

Authors:  J Connor; C Bucana; I J Fidler; A J Schroit
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide.

Authors:  A F Brownbill; D G Braun; P Dukor; G Schumann
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.

Authors:  T Asano; K Matsushima; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

6.  Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro.

Authors:  C D Bucana; L C Hoyer; A J Schroit; E Kleinerman; I J Fidler
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

Review 7.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

8.  A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.

Authors:  S Sone; T Utsugi; P Tandon; M Ogawara
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling.

Authors:  Jooeun Lee; Ivan Tattoli; Kacper A Wojtal; Stephan R Vavricka; Dana J Philpott; Stephen E Girardin
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

10.  Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid).

Authors:  E S Kleinerman; A K Raymond; C D Bucana; N Jaffe; M B Harris; I H Krakoff; R Benjamin; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.